Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plonmarlimab in Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
NCT07208058Phase 3Recruiting
- Sponsor
- TJ Biopharma
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of plonmarlimab in haemophagocytic lymphohistiocytosis (HLH), sponsored by TJ Biopharma. Started Nov 2025; status: recruiting.
02
Drugs
plonmarlimab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT07208058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208058.